Hymovis®

Hymovis^® is a sterile, hydrogel manufactured with Hyadd4 (hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation) in isotonic buffered solution.

With to the high viscosity and elasticity given by the hexadecylamide of sodium hyaluronate, Hymovis^® improves the lubricating and shock absorbing function of synovial fluid, protecting cartilage and soft tissues against mechanical injuries¹. These properties, together with the prolonged residence time in the articular joints, enable Hymovis^® to relieve pain and to improve joint function with a short treatment regimen².

Features

Recovery and improvement of the viscoelastic properties following mechanical stress¹
Prolonged residence time in the joint²
Clinical evidence up to 1 year for pain relief in patient with knee osteoarthritis^3,4
Indicated for the conservative treatment of the meniscal lesions⁵
Good safety profile^3,4

Composition: Hyadd4 (sodium hyaluronate hexadecylamide), 24 mg/3 mL

Indication: Hymovis^® is indicated to reduce pain and improve function in osteoarthritic joints and in the conservative treatment of the meniscal lesion of the knee.

Dosage: Products administration should be performed exclusively by licensed physicians.

Pack Size: Box containing 2 luer lock pre-filled syringes.

Precaution: For details, please refer to package insert.

Storage: Store in the original packaging not exceeding 25 °C. Do not freeze.

Disclaimer & Reference

The content on this site is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician with any questions you may have regarding a medical condition.

Reference

Finelli I, Chiessi E, Galesso D, Renier D, Paradossi G. A new viscosupplement based on partially hydrophobic hyaluronic acid: a comparative study. Biorheology. 2011;48(5):263-275. doi:10.3233/BIR-2011-0596
Fidia Farmaceutici S.p.A. HYMOVIS Package Insert. Accessed February 2, 2026. https://hymovis.com/wp-content/uploads/2017/04/HYMOVIS_PI.pdf
Benazzo F, Perticarini L, Padolino A, et al. A multi-centre, open label, long-term follow-up study to evaluate the benefits of a new viscoelastic hydrogel (Hymovis®) in the treatment of knee osteoarthritis. Eur Rev Med Pharmacol Sci. 2016;20(5):959-968.
Priano F. Early Efficacy of Intra-Articular HYADD® 4 (Hymovis®) Injections for Symptomatic Knee Osteoarthritis. Joints. 2017;5(2):79-84. doi:10.1055/s-0037-1603677
Zorzi C, Rigotti S, Screpis D, Giordan N, Piovan G. A new hydrogel for the conservative treatment of meniscal lesions: a randomized controlled study. Joints. 2015;3(3):136-145. doi:10.11138/jts/2015.3.3.136

Products

Related Products